Page 20 - CIBEREHD-2015-eng

Scientific Programmes
biomarkers, progression of chronic hepatitis C to cirrhosis and hepatocellular carcinoma of Hepatitis B and C.
• Most of the groups have taken part and still actively participate in multicentre clinical trials with new combinations of direct-acting antivirals against HCV.
Hepatotoxicity, Cholestasis
and Metabolic Disorders
COORDINATOR: DR. JUAN F. MEDINA
Research work connected with cholestasis and met- abolic and hepatotoxity disorders in Programme 3 is done by 10 groups. The groups directed by Doc- tors Albert Parés, Llorenç Caballería and Juan F. Medina concentrate on clinical, epidemiological and basic studies of cholestatic diseases such as cir- rhosis/primary biliary cholangitis and other chronic cholestasis. As regards basic aspects, one should also stress the research done into alterations in the transport of different components of bile, as well as in the etiopathogeny of osteopaenia associated with cholestatic syndromes. The other seven groups in the Programme cover research into metabolic dis- orders and work more specifically on the study of steatohepatitis and hepatic toxicity. These groups thus carry out studies connected with mechanisms of oxidative stress and apoptosis in hepatocytes as well as with the role of cytokines and adipocytokines in infectious, toxicological and metabolic disorders. Some very significant work is done in this respect by the groups of Dr José M. Mato and Dr José C. Femández-Checa, which have been granted a large number of competitive projects and which carry out several cooperation schemes with other groups. We should thus point out the INTERCIBER Project Under- standing obesity (Ob), metabolic syndrome (MetS), type 2 diabetes (T2DM) and fatty liver disease (FL): a multi-disciplinary approach, which, led by the CIBE- REHD (specifically, Dr José M. Mato and Dr Ma Luz Martínez-Chantar) is also actively worked on by a further three Thematic areas of the CIBER: Obesidad y Nutrición (CIBEROBN), Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and Salud Men- tal (CIBERSAM). The groups run by Doctors Javier González Gallego, Carmelo García Monzón and Pal- oma Martín Sanz also work in close cooperation for studying antioxidant therapies in models of hepatitis
C. Finally, the groups directed by Dr José V. Castell and Dr Raúl Andrade cooperate closely with each other and with the previously mentioned groups in the investigation of different molecular mechanisms producing hepatotoxicity.
Projects in the Programme and
Cooperation
CHOLESTASIS, METABOLIC DISORDERS AND HEPATOTOXICITY
The groups forming Programme 3 have over 25 co- operation networks, both between each other (in- tranodal cooperation) and with other external groups (internodal cooperation). The group led by Dr José M. Mato, from CIC BioGUNE, continues to signifi- cantly bolster these cooperation schemes through its platforms for genomics, proteomics, metabolo- mics and gene silencing, which are also available in all the CIBEREHD groups. The cooperation based on these platforms include arranging different teaching sessions and training activities.
The cooperation activities of Programme 3 are sub- stantiated in their publications in journals of great impact such as Hepatology (IF 2014: 11.055), the official journal of the American Association for the Study of Liver Diseases (AASLD), as is the case of:
• Barbier-Torres L, Beraza N, Fernández-Tussy P, Lo- pitz-Otsoa F, Fernández-Ramos D, Zubiete-Fran- co I, Varela-Rey M, Delgado TC, Gutiérrez V, An- guita J, Pares A, Banales JM, Villa E, Caballería J, Alvarez L, Lu SC, Mato JM, Martínez-Chantar ML. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. Hepatology 2015;62:1237-48.
20 I Annual report 2015 I CIBEREHD